Benzylisoquinoline alkaloid (BIA) precursor producing microbes, and methods of making and using the same

Patent metadata

Field	Value
Publication number	US-10752903-B2
Application number	US-201615567354-A
Country	US
Kind code	B2
Filing date	May 4, 2016
Priority date	May 4, 2015
Publication date	Aug 25, 2020
Grant date	Aug 25, 2020

Abstract

Methods and engineered yeast cells for generating a benzylisoquinoline alkaloid product are provided herein. A method comprises providing engineered yeast cells and a feedstock to a reactor. In the reactor, the engineered yeast cells are subjected to fermentation by incubating the engineered yeast cells for a time period to produce a solution comprising the BIA product and cellular material. The solution comprises not more than one class of molecule selected from the group of protoberberine, morphinan, isopavine, aporphine, and benzylisoquinoline. Additionally, at least one separation unit is used to separate the BIA product from the cellular material to provide the product stream comprising the BIA product.

First claim

What is claimed is:

1. A method for forming a product stream having a benzylisoquinoline alkaloid product, the method comprising:
(a) providing engineered non-plant cells and a feedstock including nutrients and water to a batch reactor, which engineered non-plant cells have modifications that result in overproduction of a derivative of tyrosine, along a pathway to produce the benzylisoquinoline alkaloid product, with respect to a non-engineered non-plant cell, wherein the modifications comprise at least three modifications, wherein at least one modification of the at least three modifications is a transcriptional modulation mutation or an inactivating mutation, and wherein each modification of the at least three modifications is selected from the group consisting of: a feedback inhibition alleviating mutation, a transcriptional modulation mutation, and an inactivating mutation, wherein a first modification of the at least three modifications is associated with a first enzyme, a second modification of the at least three modifications is associated with a second enzyme, and a third modification of the at least three modifications is associated with a third enzyme, and wherein each enzyme of the first, second, and third enzymes is distinct from any other enzyme of the first, second, and third enzymes, and wherein each enzyme of the first, second, and third enzyme is selected from the group consisting of: transketolase, glucose-6-phosphate dehydrogenase, pentafunctional AROM protein, 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase, chorismate mutase, tyrosinase, tyrosine hydroxylase, L-DOPA decarboxylase, monoamine oxidase, aromatic/aminoadipate aminotransferase, aromatic aminotransferase, phenylpyruvate decarboxylase, alcohol dehydroxylase 2, alcohol dehydroxylase 3, alcohol dehydroxylase 4, alcohol dehydroxylase 5, alcohol dehydroxylase 6, alcohol dehydroxylase 7, aldehyde oxidase 2, aldehyde oxidase 3, aldehyde oxidase 4, aldehyde oxidase 5, and aldehyde oxidase 6;
(b) in the batch reactor, subjecting the engineered non-plant cells to fermentation by incubating the engineered non-plant cells for a time period of at least 5 minutes to produce a solution comprising the benzylisoquinoline alkaloid product and cellular material; and
(c) using at least one separation unit to separate the benzylisoquinoline alkaloid product from the cellular material to provide the product stream comprising the benzylisoquinoline alkaloid product, wherein the separation unit comprises a component selected from the group consisting of: a chromatography component, a precipitation component, a filtration component, an extraction component, and a sedimentation component.

2. The method of claim 1 , wherein the engineered non-plant cells are engineered fungal cells.

3. The method of claim 2 , wherein the engineered fungal cell comprises one or more feedback inhibition alleviating mutations in one or more biosynthetic enzyme genes that encode 3-deoxy-d-arabinose-heptulosonate-7-phosphate synthase.

4. The method of claim 2 , wherein the engineered fungal cell comprises one or more feedback inhibition alleviating mutations in one or more biosynthetic enzyme genes that encode chorismate mutase.

5. The method of claim 2 , wherein the engineered fungal cell further comprises at least one transcriptional modulation modification in a biosynthetic enzyme gene.

6. The method of claim 1 , wherein at least one process parameter of the batch reactor is modifiable to alter a resultant benzylisoquinoline alkaloid product composition, wherein the at least one process parameter that is modifiable comprises at least one of dissolved oxygen, pH, stirring speed, aeration rate, and cell density.

7. The method of claim 1 , wherein the benzylisoquinoline alkaloid product is selected from the group of norcoclaurine, norlaudanosoline, tyramine, 4-hydroxyphenylacetaldehyde, 4-hydroxyphenylpyruvic acid, L-3, 4-dihydroxyphenylalanine, 3,4-dihydroxyphenylacetaldehyde, and dopamine.

8. The method of claim 1 , wherein the benzylisoquinoline alkaloid product is a benzylisoquinoline alkaloid that has a structural class that is selected from the group of benzylisoquinolines, protoberberines, protopines, benzophenanthridines, promorphinans, morphinans, secoberbines, phthalideisoquinolines, aporphines, and bisbenzylisoquinolines.

9. The method of claim 1 , wherein the product stream does not contain more than 5 ppm of a molecule selected from the group of lignin, pigments, flavonoids, phenanthreoids, latex, rubisco, meconic acid, pseudomorphine, narceine, thebaol, and pollen.

10. The method of claim 1 , wherein the product stream does not contain a detectable amount of a substance selected from the group consisting of pesticides, fungicides, or herbicides.

11. The method of claim 2 , wherein the engineered fungal cell comprises two or more heterologous coding sequences, wherein the two or more heterologous coding sequences encode at least a first enzyme and a second enzyme that are involved in a metabolic pathway that converts the tyrosine into the benzylisoquinoline alkaloid product, wherein the first enzyme and second enzyme are operably connected along the metabolic pathway.

12. The method of claim 2 , wherein the engineered fungal cell comprises three heterologous coding sequences, wherein the three heterologous coding sequences encode a first enzyme, second enzyme, and third enzyme that are involved in a metabolic pathway that converts the tyrosine into the benzylisoquinoline alkaloid product, wherein the first enzyme, second enzyme, and third enzyme are operably connected along the metabolic pathway.

Assignees

• Univ Leland Stanford Junior

Inventors

• Smolke Christina D
• Thodey Catherine
• Trenchard Isis

Classifications

• C07D217/22

  with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring · CPC title

• C12P17/12

  containing a six-membered hetero ring · CPC title

• C07D217/18

  Aralkyl radicals · CPC title

• C12Y401/01028

  Aromatic-L-amino-acid decarboxylase (4.1.1.28), i.e. tryptophane-decarboxylase · CPC title

• C12Y114/16002

  Tyrosine 3-monooxygenase (1.14.16.2) · CPC title